SAM
PTGX icon

Smartleaf Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Smartleaf Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$108K Hold
890
– – ﹤0.01% 1136
2026
Q1 		$88.9K Sell
890
-837
-48% -$74.1K ﹤0.01% 1180
2025
Q4 		$151K Buy
1,727
+324
+23% +$26.5K 0.01% 958
2025
Q3 		$91.4K Buy
1,403
+146
+12% +$8.3K 0.01% 1121
2025
Q2 		$70K Buy
1,257
+46
+4% +$2.21K 0.01% 1014
2025
Q1 		$59.2K Buy
1,211
+710
+142% +$29.8K 0.01% 1062
2024
Q4 		$19.3K Buy
501
+411
+457% +$17.9K ﹤0.01% 1659
2024
Q3 		$4.01K Buy
90
+75
+500% +$3.03K ﹤0.01% 2220
2024
Q2 		$478 Buy
+15
New +$439 ﹤0.01% 2557

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Smartleaf Asset Management's PTGX Position: Q2 2026 in Review

Smartleaf Asset Management held its Protagonist Therapeutics (PTGX) position steady in Q2 2026 at 890 shares worth $108K. The position accounts for ﹤0.01% of the portfolio, ranked #1136.

Smartleaf Asset Management first reported a position in PTGX in Q2 2024 and has held it in 9 quarters since. The position peaked at $151K in Q4 2025. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Smartleaf Asset Management held 890 shares of Protagonist Therapeutics worth $108K as of Q2 2026.
  • Smartleaf Asset Management left its Protagonist Therapeutics share count unchanged in Q2 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #1136 holding.
  • Smartleaf Asset Management first reported a position in Protagonist Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Smartleaf Asset Management's Protagonist Therapeutics position peaked at $151K in Q4 2025.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.